GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
4.6k
c/retatrutide·posted 2 years ago by u/dead_space_doug

[Lab] split one vial across Janoshik and Medutest — 95.1% and 99.3%

Lab Clean Column ×8 Slow Clap ×1 Well Actually ×1

split one vial across Janoshik and Medutest — 95.1% and 99.3%. I will put the method line and the batch identifier up front because that is what makes this checkable.

95.1% and 99.3%. Those are measured, not estimated, and not rounded up in my favour.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Tell me where this is wrong. That is the useful part of posting it.

5,658 up / 1,037 down85% upvoted42 commentsid giua1w16 Jul 2024

42 comments

19 in this archive, depth 4

best — the order this archive was captured in

u/reta_and_regretMOD1k points·2 years ago

Left up. It reads the phase 2 paper carefully and it is honest about the intervals.

replysharereportpermalink
u/ewan_marchand1.5k points·2 years ago

Left up.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

replysharereportpermalink
u/rohan_cardoso2.3k points·2 years ago

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

replysharereportpermalink
u/marta_vanhecke0 points·2 years ago

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

replysharereportpermalink
u/dead_space_dougOP1 point·2 years ago

nothing here is available as a prescription product, so read every thread with that in mind

replysharereportpermalink
u/priya_weiss1 point·2 years ago

the TRIUMPH programme is still running, so anything definitive is premature

replysharereportpermalink
u/matias_falk1 point·2 years ago

phase 2 data only, and people quote it like it is a label

replysharereportpermalink
u/mateusz_mensah1 point·2 years ago

The thing that surprised me was how much of the discussion here is inference rather than measurement.

replysharereportpermalink
u/two_mil_or_one-1 point·2 years ago

Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.

replysharereportpermalink
u/clara_weiss1 point·2 years ago

a lot of the confident posting here is extrapolation

replysharereportpermalink
u/blunt_coldbox_20241 point·2 years ago

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

replysharereportpermalink
u/honest_syringe_20251 point·2 years ago

comparing reta phase 2 to sema phase 3 is comparing different things

replysharereportpermalink
u/aa_analysis_andy341 points·2 years ago

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

replysharereportpermalink
u/dead_space_dougOP182 points·2 years ago

What is the source for that figure — the published paper or a summary of it?

replysharereportpermalink
u/reflux_report79 points·2 years ago

not approved anywhere, which is the single most important fact in this board

replysharereportpermalink
u/employer_carveout66 points·2 years ago

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

replysharereportpermalink
[deleted]126 points·2 years ago

[deleted]

replysharereportpermalink
u/dead_space_dougOP55 points·2 years ago·edited

Is that the 48-week figure or an earlier readout?

replysharereportpermalink
load more comments (1) →
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.